STOCK TITAN

Ikena Oncology, Inc. - IKNA STOCK NEWS

Welcome to our dedicated news page for Ikena Oncology (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ikena Oncology 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ikena Oncology 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
Ikena Oncology, Inc.

Nasdaq:IKNA

IKNA Rankings

IKNA Stock Data

62.74M
17.90M
7%
100.01%
2.59%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BOSTON

About IKNA

ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi